- Login
- Register & Subscribe
- Language: EN FR DE
Company News
FDA approves prostate treatment from GSK
Tuesday 15 June 2010
GlaxoSmithKline said that the US Food and Drug Administration has approved its combination treatment for benign prostatic hyperplasia, Jalyn. The drug combines dutasteride and tamsulosin in a single capsule.
Location
United Kingdom
See map: Google Maps
Genmab’s chief executive retires
Tuesday 15 June 2010
Genmab A/S, which develops antibodies for cancer, announced on 15 June 2010 the retirement of its chief executive, Lisa Drakeman, who has served in that post since the Danish company was founded in 1999.
Location
Denmark
Phase-3 trial for non-small-cell lung cancer fails
Monday 14 June 2010
Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals Inc announced that a Phase 3 trial of Nexavar (sorafenib) failed to reach its primary endpoint of improving overall survival in study of some 900 patients with advanced non-squamous, non-small-cell lung cancer.
Location
United States
See map: Google Maps
Pharnext raises €4.8 million for trial of combination drug
Friday 11 June 2010
A three-year-old French biopharmaceutical company, Pharnext SAS, has raised €4.8 million in a Series A round to take a new combination drug into the clinic to treat an inherited neurological disorder known as Charcot-Marie-Tooth disease.
Location
France
FDA Advisory Committee recommends MS drug
Friday 11 June 2010
An advisory committee of the US Food and Drug Administration has recommended that the multiple sclerosis drug, fingolimod, be approved, according to Novartis, the drug’s manufacturer. The drug is an oral therapy that has a novel mode of action.
Location
Switzerland
See map: Google Maps
UCB raises stake in Wilex to 18.05%
Thursday 10 June 2010
UCB SA of Belgium has raised its stake in the German biopharmaceutical company, Wilex AG, to 18.05% from 11.4% following the purchase of a block of shares from a fund managed by Apax Partners. The transaction was reported on 10 June 2010.
Location
Belgium
Ipsen implements ADR programme
Thursday 10 June 2010
Ipsen SA of France will be listed on the over-the-counter market in the US following its agreement with Deutsche Bank to implement a level 1 American Depositary Receipt (ADR) programme. The company’s shares are already listed in Paris.
Location
France
Apogenix progresses study of cancer agent
Wednesday 9 June 2010
Apogenix GmbH of Heidelberg, Germany has begun recruitment for a Phase 2 study of a compound for treating glioblastoma multiforme, the most aggressive type of primary brain tumour. Interim results are expected in the first half of 2011.
Location
Germany
See map: Google Maps
Sanofi Pasteur to develop antibodies against infectious diseases
Tuesday 8 June 2010
Sanofi Pasteur has become the second European company in a month to invest in antibody technology in order to discover new treatments for infectious diseases. It is paying €3 million upfront to Vivalis of France for access to the technology.
Location
France
French immune therapy company raises €12 million
Monday 7 June 2010
The French privately-owned immune therapy company, Cytheris SA, has raised €12 million in a Series D financing to accelerate development of its recombinant human interleukin-7 product, CYT107, for cancer and other indications.
Location
France
Select a News Category
Recent Appointments
Tim Edwards elected chairman of BIA
Tuesday September 7 2010
Index Ventures appoints antibody expert as partner
Friday September 3 2010
Colin Stewart appointed CEO at Amarin
Friday August 20 2010
Karl Keegan nominated as CFO of Pharming
Friday August 20 2010
Axel Müller becomes CEO at SkyePharma
Thursday August 19 2010